Back to Journals » Infection and Drug Resistance » Volume 14

Immunological Aspects of Diagnosis and Management of Childhood Tuberculosis

Authors Gutiérrez-González LH, Juárez E, Carranza C, Carreto-Binaghi LE, Alejandre A, Cabello-Gutiérrrez C, Gonzalez Y

Received 4 December 2020

Accepted for publication 11 February 2021

Published 8 March 2021 Volume 2021:14 Pages 929—946

DOI https://doi.org/10.2147/IDR.S295798

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Suresh Antony


Luis Horacio Gutiérrez-González,1 Esmeralda Juárez,2 Claudia Carranza,2 Laura E Carreto-Binaghi,2 Alejandro Alejandre,3 Carlos Cabello-Gutiérrrez,1 Yolanda Gonzalez2

1Virology and Mycology Department, National Institute for Respiratory Diseases Ismael Cosío Villegas, Mexico City, Mexico; 2Microbiology Department, National Institute for Respiratory Diseases Ismael Cosío Villegas, Mexico City, Mexico; 3Pediatric Clinic, National Institute for Respiratory Diseases Ismael Cosío Villegas, Mexico City, Mexico

Correspondence: Yolanda Gonzalez
Microbiology Department, National Institute for Respiratory Diseases Ismael Cosío Villegas, Calzada de Tlalpan 4502, Sección XVI, Alcaldía de Tlalpan, 14080, Mexico City, México
Tel +52 55 5487 1700 Ext. 5117
Email [email protected]

Abstract: The diagnosis of tuberculosis (TB) in children is difficult because of the low sensitivity and specificity of traditional microbiology techniques in this age group. Whereas in adults the culture of Mycobacterium tuberculosis (M. tuberculosis), the gold standard test, detects 80% of positive cases, it only detects around 30– 40% of cases in children. The new methods based on the immune response to M. tuberculosis infection could be affected by many factors. It is necessary to evaluate the medical record, clinical features, presence of drug-resistant M. tuberculosis strains, comorbidities, and BCG vaccination history for the diagnosis in children. There is no ideal biomarker for all TB cases in children. A new strategy based on personalized diagnosis could be used to evaluate specific molecules produced by the host immune response and make therapeutic decisions in each child, thereby changing standard immunological signatures to personalized signatures in TB. In this way, immune diagnosis, prognosis, and the use of potential immunomodulators as adjunct TB treatments will meet personalized treatment.

Keywords: TB, immune status, diagnosis, TB-treatment, coinfections, personalized diagnosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]